Essentials
• Mice lacking factor IX (FIX) or factor XI (FXI) were tested in a saphenous vein bleeding model.
• FIX-deficient mice displayed a hemostatic defect and FXI-deficient mice were similar to wild type mice.
• Infusion of FXI or over-expression of FXI in FIX-deficient mice improved hemostasis.
• FXI may affect the phenotype of FIX-deficiency (hemophilia B).
Summary. Background:
In humans, deficiency of coagulation factor XI may be associated with a bleeding disorder, but, until recently, FXI-deficient mice did not appear to have a hemostatic abnormality. A recent study, however, indicated that FXI-deficient mice show a moderate hemostatic defect in a saphenous vein bleeding (SVB) model. Objectives: To study the effect of FXI on bleeding in mice with normal levels of the FXI substrate FIX and in mice lacking FIX (a murine model of hemophilia B 
Introduction
Factor XI is the precursor of a plasma protease (FXIa) that contributes to thrombin generation primarily through activation of FIX [1] . FXI deficiency was first described in humans in 1953 as plasma thromboplastin antecedent deficiency, a condition associated with a significant defect in surface-induced plasma coagulation, but a relatively mild propensity for abnormal bleeding [2] [3] [4] . FXI-deficient patients seldom experience unprovoked hemorrhage, and excessive bleeding typically follows trauma to tissues with high intrinsic fibrinolytic activity, such as the mouth, nose, or urinary tract. Experience with FXI deficiency in humans indicates that the protein is required for hemostasis in some individuals for certain types of hemostatic challenge. However, it is clear that some people with severe FXI deficiency do not experience abnormal hemostasis, suggesting that variables unrelated to the plasma FXI level contribute to bleeding in FXI-deficient individuals. FXI deficiency has been linked to abnormal hemostasis in domesticated animals (cattle, dogs, and cats) [5] [6] [7] , but not in several species commonly used in preclinical research. Rodents, rabbits and primates treated with a variety of agents that inhibit FXI/FXIa activity [8] [9] [10] or block FXI synthesis [11, 12] do not show an unusual bleeding propensity. We, and others, did not observe abnormal hemostasis in FXI-deficient (F11 species. Given this, we were interested in the recent report by Ay et al. describing abnormal hemostasis in F11 À/À mice after saphenous vein injury [15] . Here, we describe our experience with a saphenous vein bleeding (SVB) model, and report that FXI can affect bleeding in mice with hemophilia B (FIX deficiency).
Methods

Mice
Studies with mice were approved by the Vanderbilt University Medical Center Institutional Animal Care and Use Committee. C57Bl/6 male mice lacking FIX (F9 À ) or FXI (F11 À/À ) have been described previously [13, 16] 
Thrombin generation assay
Thrombin generation was measured in plasma as described previously [22, 23] . Briefly, FIX-deficient plasma (80 lL) containing 415 lM Z-Gly-Gly-Arg-AMC (Bachem, Torrance, CA, USA) was supplemented with TF (1 pM) with or without FXIa (15 nM). Additives were applied in 20-lL volumes, and the concentrations given are final concentrations. Thrombin generation was initiated by adding 10 lL of 20 mM HEPES (pH 7.4), 100 mM CaCl 2 , and 6% bovine serum albumin, and fluorescence was monitored over a period of 60 min on a Fluoroskan Ascent fluorometer (Thermolab Systems OY, Helsinki, Finland). Thrombin generation was calculated with the calibrated automated thrombogram software THROMBINOSCOPE.
Results and discussion
Bleeding after saphenous vein injury was significantly more severe in F9 À mice than in wild-type mice (P < 0.05), as reflected by fewer bleeding episodes (Fig. 1A , white) and a longer duration of each bleed (Fig. 1B) . The results are consistent with published data [15, 17] . In contrast to the results reported by Ay et al.
[15], we did not observe significant differences between C57Bl/6 wild-type and F11 À/À mice in the number of clots (Fig. 1A) , average bleeding time (Fig. 1B) , time to first clot formation (Fig. 1C) , or average times of subsequent bleeding events (Fig. 1D ). The differences between our results and those of Ay et al. could easily reflect subtle differences in technique, including the degree of injury and the manner in which clots were disturbed. Also, although the F11 À/À mice used in the two studies are of the same lineage [13] , the colonies at the two institutions 
Previously, Whelihan et al. and our group observed that FXIa activates plasma coagulation factors other than FIX (FV, FVIII, and FX) [24, 25] . This may explain the observation that mice lacking both FIX and FXI are more resistant to arterial thrombosis than mice lacking only FIX [25] , and supports the notion that FXIa can promote thrombin generation independently of FIX. We did not find evidence for a role for FXI in hemostasis in C57Bl/6 mice when we used the SVB model. However, on the basis of our experience with thrombosis models, we For all panels, blots were developed with the monoclonal IgG 14E11 [21] , which was raised against mouse FXI in an F11 À/À mouse, and which recognizes mouse and human FXI. reasoned that we might be able to detect a prohemostatic effect in mice in the absence of FIX. The data presented here support the notion that FXIa can influence the coagulation mechanism 'downstream' from FIX. Infusing FXIa increased the number of clotting episodes and reduced bleeding duration in F9 À mice (Fig. 1A, gray) . A similar effect can be produced in plasma clotting (Fig. 1E ) and thrombin generation (Fig. 1F) assays by using small amounts of TF to start thrombin generation. In F9 À mice given FXIa, the duration of bleeding was shortest for early bleeds, and became longer with time (data not shown), consistent with inhibition of FXIa by plasma protease inhibitors. In contrast, raising the plasma FXI level to > 200% had a more sustained prohemostatic effect, suggesting that infusion of FXI enhanced FXIa generation over time.
Results similar to those obtained with FXI infusion were achieved by overexpressing human FXI in F9 À mice by the use of HTI (Fig. 1A , black) [26] . The CAG promoter in the EEV600A vector supports sustained FXI expression for at least 4 weeks ( Fig. 2A) , and results in plasma levels of human FXI that are five-fold to sevenfold higher than the endogenous FXI level of mice (Fig. 2B,C) [27] . The FXI variant FXI-A183-185 has alanine replacements for three residues that are required to form a FIX-binding exosite [20] . FXIa-A183-185 has a severe defect in FIX activation [20] , but activates FX [25] and FV (data not shown) similarly to wild-type FXIa.
The defect in FXI-A183-185 is obvious in a model in which carotid artery occlusion is induced by FeCl 3 exposure [14, 21] . Thrombosis in this model depends on FIX and FXI. Consistent with this, the resistance of F11 À/À mice to thrombus formation is reversed by FXI-WT but not by FXI-A183-185 (Fig. 2D) . FXI with its A3 domain (which contains residues 183-185) replaced with the A3 domain from the homologous protein prekallikrein has a similar defect (Fig. 2D) . Furthermore, the resistance of F9 À mice to FeCl 3 -induced thrombosis cannot be reversed by overexpressing FXI-WT. These findings emphasize the importance of FXIa activation of FIX in the thrombosis model. In contrast, in the SVB model, FXI-WT and FXI-A183-185 improved hemostasis in F9 À mice to similar extents, consistent with FXIa exerting a prohemostatic effect independently of FIX (Fig. 1A,B) . Although the plasma FXI/XIa levels used in our studies were supraphysiological, the results suggest that differences in FXI plasma levels, or differences in the ability to generate FXIa, could contribute to the variability in bleeding tendency in patients with FIX deficiency (hemophilia B). They also raise the possibility that supraphysiological FXIa or FXI could be used in patients with FIX or FVIII inhibitors to promote hemostasis in a manner similar to that of recombinant FVIIa or activated prothrombin complex preparations. Indeed, the long plasma half-life of FXI (~50 h) would be an advantage over currently used preparations. However, we doubt that infusions of wild-type FXI or FXIa would be practical. The use of FXI concentrates in FXI-deficient patients has been associated with thrombotic events, particularly in older individuals with cardiovascular risk factors [28, 29] . With these concentrates, contaminating FXIa is suspected to be the prothrombotic culprit, suggesting that FXIa infusions would not be safe. Perhaps a modified FXIa, such as FXIa-A183-185, that does not activate FIX might be safer.
Although our results differ from those reported by Ay et al. regarding the behavior of F11 À/À mice in the SVB model, the data generated with F9 À animals do support their conclusion that FXI can contribute to hemostasis in mice with some types of injury [15] . However, we suspect that differences in sensitivity to FXI of the SVB assays used in different laboratories, and the relatively small differences in bleeding tendency observed, will make this method difficult to use for studying the role of FXI in hemostasis. It is notable that Ay et al. did not detect differences between F11 À/À and wild-type mice in a tail bleeding assay or in mice with abdominal surgical wounds [15] . In the past, we did not observe differences in tail bleeding between these mouse lines [14] , or in a liver laceration model (data not shown). This is consistent with the observation that hemorrhage in FXI-deficient humans, if it occurs, tends to involve certain types of tissue [2] [3] [4] . 
